<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38152">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609828</url>
  </required_header>
  <id_info>
    <org_study_id>A4091061</org_study_id>
    <secondary_id>2013-002223-42</secondary_id>
    <secondary_id>CANCER PAIN PH 3 SC STUDY</secondary_id>
    <nct_id>NCT02609828</nct_id>
  </id_info>
  <brief_title>Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.</brief_title>
  <official_title>A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of The Subcutaneous Administration Of Tanezumab (Pf-04383119) In Subjects With Cancer Pain Predominantly Due To Bone Metastasis Receiving Background Opioid Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether tanezumab is effective in the treatment of
      cancer pain due to bone metastasis in patients already taking background opioid therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter, parallel-group Phase 3
      study in cancer subjects requiring treatment with background opioids for pain due to bone
      metastasis.

      Approximately 170 subjects will be randomized to one of 2 treatment groups in a 1:1 ratio
      (approximately 85 subjects per group). Subjects will receive a total of 3 subcutaneous
      injections, separated by 8 weeks in addition to background opioids administered throughout
      the study.

      Treatment groups will include: 1. Placebo SC (matching tanezumab SC) in addition to
      background opioid therapy. 2. Tanezumab 20 mg SC in addition to background opioid therapy.

      The study consists of three periods: Pre-Treatment (up to 37 days), Double-Blind Treatment
      (24 weeks) and Safety Follow-up (24 weeks).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2015</start_date>
  <completion_date type="Anticipated">January 26, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in daily average pain intensity in index bone metastasis cancer pain site</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from Baseline to Week 8 in the daily average pain intensity Numerical Rating Score (NRS) in the index bone metastasis cancer pain site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daily average pain intensity in index bone metastasis cancer pain site</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 1, 2, 4, 6, 12, 16 and 24 in the daily average pain intensity NRS score in the index bone metastasis cancer pain site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daily worst pain intensity in index bone metastasis cancer pain site</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the daily worst pain intensity NRS score in the index bone metastasis cancer pain site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly average pain intensity in non-index cancer pain sites</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the weekly average pain intensity NRS score in non-index cancer pain sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly worst pain intensity in non-index cancer pain sites</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the weekly worst pain intensity NRS score in non-index cancer pain sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daily average pain intensity in non-index visceral cancer pain sites</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the daily average pain intensity NRS score in the non-index visceral cancer pain sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daily worst pain intensity in non-index visceral cancer pain sites</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 in the daily worst pain intensity NRS score in the non-index visceral cancer pain sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Brief Pain Inventory (BPI) average pain score</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 2, 4, 8, 16 and 24 in the Brief Pain Inventory (BPI) average pain scores obtained at study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BPI worst pain score</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 2, 4, 8, 16 and 24 in the BPI worst pain scores obtained at study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response as defined by a 30%, 50%, 70%, and 90% reduction from Baseline in the daily average and daily worst pain intensity NRS score in the index bone metastasis cancer pain site</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Response as defined by a 30%, 50%, 70%, and 90% reduction from baseline in the daily average and daily worst pain intensity NRS score in the index bone metastasis cancer pain site at Weeks 1, 2, 4, 6, 8, 12, 16 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient's Global Assessment of Cancer Pain</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline in Patient's Global Assessment of Cancer Pain at Weeks 2, 4, 8, 16 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response defined as an improvement of 2 points in Patient's Global Assessment of Cancer Pain</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Response defined as an improvement of 2 points in Patient's Global Assessment of Cancer Pain at Weeks 2, 4, 8, 16 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the BPI Pain Interference with Function composite score and individual pain interference item scores</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline to Weeks 2, 4, 8, 16 and 24 in the BPI Pain Interference with Function Composite Score and individual pain interference item scores obtained at study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol 5 Dimension (EQ-5D-5L) dimensions and overall health utility score</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>EuroQol 5 Dimension (EQ-5D-5L) dimensions and overall health utility score at Baseline and Weeks 8, 16 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily total opioid consumption (in mg of morphine equivalent doses)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Average daily total opioid consumption (in mg of morphine equivalent doses) at Weeks 1, 2, 4, 6, 8, 12, 16 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average number of doses of rescue medication required per week</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Average number of doses of rescue medication required per week at Weeks 1, 2, 4, 6, 8, 12, 16 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly Opioid-Related Symptom Distress Scale</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Change from Baseline in the weekly Opioid-Related Symptom Distress Scale at Weeks 2, 4, 8, 16, and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Summary listing of adverse events for each participant; Summary of risk differences between each tanezumab group and placebo for common adverse events and for selected adverse events of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard safety assessments</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Summary listing of safety laboratory testing [chemistry, hematology], sitting vital signs, ECG [12-lead]) for each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orthostatic (supine/standing) blood pressure assessment</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Orthostatic (supine/standing) blood pressure assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight and Height measurements, Physical examinations.</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Weight measurements (pounds or kilograms), Height measurements (inches or centimeters), Body Mass Index (kg per meter squared), Physical examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic examination (Neuropathy Impairment Score [NIS]).</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Neurologic examination (Neuropathy Impairment Score [NIS]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survey of Autonomic Symptom scores</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Survey of Autonomic Symptom scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody (ADA) assessments</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Anti-drug antibody (ADA) assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint safety adjudication outcomes</measure>
    <time_frame>Up to 48 weeks, or up to 24 weeks following total joint replacement procedure</time_frame>
    <description>Number of subjects with adjudicated events of rapidly progressive osteoarthritis type 2, subchondral insufficiency fractures or spontaneous osteonecrosis of the knee, primary osteonecrosis, or pathological fracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total joint replacements</measure>
    <time_frame>Up to 24 weeks post-procedure</time_frame>
    <description>Total joint replacements</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <condition>Musculoskeletal Pain</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tanezumab 20 mg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to active treatment subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tanezumab</intervention_name>
    <description>Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>PF-04383119</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Personally signed and dated informed consent document.

          -  Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other study procedures.

          -  Male or female, ≥18 years of age

          -  Weight ≥40 kg at Screening

          -  Cancer diagnosed as having metastasized to bone or multiple myeloma.

          -  Imaging confirmation of bone metastasis at Screening or within 120 days prior to the
             Screening visit.

          -  Expected to require daily opioid medication throughout the course of the study.

          -  Willing to not use prohibited medications (including NSAIDs) throughout the duration
             of the study.

          -  Average Pain Score ≥5 at Screening for the index bone metastasis cancer pain site.

          -  Patient's Global Assessment of Cancer Pain of &quot;fair&quot;, &quot;poor&quot; or &quot;very poor&quot; at
             Screening.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0, 1, or 2 at
             Screening.

          -  Adequate bone marrow, renal and liver function at Screening.

          -  International Normalized Ratio (INR) or prothrombin time (PT) &lt;1.5 x ULN at Screening
             unless being treated with anticoagulant medication.

          -  Females must either be not of childbearing potential or, if of childbearing potential
             and at risk for pregnancy, must be willing to use at least one highly effective
             method of contraception throughout the study and for 112 days (16 weeks) after the
             last dose of assigned subcutaneous study medication.

        Exclusion Criteria:

          -  Pain related to an oncologic emergency.

          -  Brain metastasis or leptomeningeal metastasis.

          -  Presence of hypercalcemia at Screening.

          -  Pain primarily classified as not predominantly related to a bone metastasis.

          -  Systemic treatment for the primary malignancy or bone metastasis started within 30
             days of the Baseline Assessment Period.

          -  In Japan only, chemotherapies associated with peripheral neuropathy (ie, paclitaxel,
             docetaxel, oxaliplatin, cisplatin, vincristine, thalidomide or bortezomib) are
             prohibited during study period from 30 days prior to the first day of the Baseline
             Assessment Period to Week 32.

          -  Receipt of radiopharmaceutical treatment or radiotherapy for treatment of bone
             metastasis within 30 days of the Baseline Assessment Period.

          -  Concurrent adjuvant analgesics unless started at least 30 days prior to the start of
             the Baseline Assessment Period and maintained at a stable dose.

          -  Diagnosis of osteoarthritis of the knee or hip or findings consistent with
             osteoarthritis in the shoulder.

          -  History of significant trauma or surgery to a major joint within one year prior to
             Screening.

          -  History of osteonecrosis or osteoporotic fracture.

          -  X-ray evidence at Screening of: 1) rapidly progressive osteoarthritis, 2) atrophic or
             hypotrophic osteoarthritis, 3) subchondral insufficiency fracture, 4) spontaneous
             osteonecrosis of the knee (SPONK), 5) osteonecrosis, or 6) pathologic fracture.

          -  Signs and symptoms of clinically significant cardiac disease.

          -  Evidence of orthostatic hypotension at Screening or at Baseline prior to
             randomization.

          -  Diagnosis of a transient ischemic attack in the 6 months prior to Screening or
             diagnosis of stroke with significant residual deficits.

          -  History, diagnosis, or signs and symptoms of clinically significant neurological
             disease.

          -  Total impact score of &gt;7 on the Survey of Autonomic Symptoms (SAS) at Screening.

          -  Past history of carpal tunnel syndrome (CTS) with signs or symptoms of CTS in the one
             year prior to Screening.

          -  History of significant alcohol, analgesic, or narcotic substance abuse within the six
             months prior to Screening.

          -  Planned surgical procedure during the duration of the study.

          -  Considered unfit for surgery or not willing to undergo joint replacement surgery if
             required.

          -  Known hypersensitivity to opioids or an underlying medical condition contraindicating
             opioid use.

          -  History of allergic or anaphylactic reaction to a therapeutic or diagnostic
             monoclonal antibody or IgG-fusion protein.

          -  Previous exposure to exogenous nerve growth factor or to an anti-nerve growth factor
             antibody.

          -  Presence of drugs of abuse, prescription medications without a valid prescription or
             other illegal drugs at Screening.

          -  Positive Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) tests at
             Screening indicative of current infection.

          -  Investigational site staff members and their family members, or Pfizer employees
             directly involved in the conduct of the trial.

          -  Participation in other studies involving investigational drug(s) within 30 days (or
             90 days for investigational biologics) before Baseline Assessment Period and/or
             during study participation.

          -  Pregnant female subjects; breastfeeding female subjects; female subjects of
             childbearing potential who are unwilling or unable to use one (1) highly effective
             method of contraception throughout the study and for 112 days after last dose of
             investigational product.

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Karapetis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Flinders cancer innovation centre, Flinders Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Milhomem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro de Pesquisas Clinicas da Fundação Hospital Amaral Carvalho</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernanda Damian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>União Brasileira de Educação e Assintência Hospital Sao Lucas DA PUCRS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rudolf Likar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Anesthesiology and Intensiv Care Medicine, Klinikum Klagenfurt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ludmila Koch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Cruz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IBCC - Instituto Brasileiro de Controle do Câncer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra Serrano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacao Antonio Prudente - Hospital A.C. Camargo/Hospital do Cancer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Smakal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology department of Nemocnice Benesov</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jiri Klecka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Site Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Petra Panovcova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemocnice Horovice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ondrej Slama, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masarykuv onkologicky ustav, Klinika komplexni onkologicke pece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zbigniew Nowecki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MSCM Cancer Center and Institute Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Viliam Cibik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Slovak Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lubomira Nemcikova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology and pain out patient clinic/NCI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keon Uk Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology/Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joo Hyuk Sohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Fallon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edinburgh Cancer Research Centre (IGMM)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Barrett-Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Velindre Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandro Orts Castro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sanitas La Moraleja</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lee Na Teo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ballarat Health Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuliano Borges, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica de Neuoplasias Litoral - Centro de Novos Tratamentos Itajaí</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tiago Biachi de Castria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Cancer do Estado de Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung Hye Kwon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Kangdong Sacred Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pavol Demo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ambulancia Klinickej onkologie FNsP Nove Zamky</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jitka Fricova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georg Nuhr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nuhr Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Santi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina do ABC/CEPHO - Centro de Estudos e Pesquisa em Hematologia e Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susanne Costa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Câncer - INCA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Poulain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Polyclinique de L'ormeau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrzej Stachowiak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pallmed Sp. z o.o. NZOZ Dom Sue Ryder</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maciej Sopata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poradnia Medycyny Paliatywnej Hospicjum Palium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Jara Sanchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Fundacion de Alcorcon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Salete Nascimento, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital do Cancer de Barretos Fundacao Pio XII</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tatiana Pietrzynska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Powiatowy Zespo Zakadow Opieki Zdrowotnej w Bdzinie, Oddzia Opieki Paliatywnej Szpital Czelad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Agnieszka Kluczna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Niepliczny Zakad Opieki Zdrowotnej Zespo Medyczno-Opieku-Czy Alicja Kluczna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ancor Serrano Afonso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>L'Hospitalet de Llobregat</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Franco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash Medical Centre - Moorabin Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magdalena Korozan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospicjum im. Ks. Eugeniusza Dutkiewicza SAC w Gdansku</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcin Janecki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stowarzyszenie Przyjacio Chorych Hospicjum w Gliwicach NZOZ Hospicjum Miosierdzia Boego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hedviga Jakubikova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sanera, s.r.o. Neurologicka a algeziologicka ambulancia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>César Margarit Ferri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Dd Alicante</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae-Yong Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology/ Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Concepción Pérez Hernández, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Princesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk Forstmeyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Leipzig AöR Universitäres Krebszentrum Leipzig (UCCL)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tibor Csoszi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hetenyi G Korhaz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laszlo Landherr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uzsoki utcai Kórház</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andras Telekes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bajcsy-Zsilinszy Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roxana Ioana Scheusan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncocenter Onclogie Clinica S.R.L</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Lungulescu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SC Oncolab SRL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Crihana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology at CF Clinical Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Burkhard Gustorff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wilhelminenspital der Stadt Wien</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zsofia Polya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Josa András Teaching Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jinsoo Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Schenker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SF Nectarie Oncology Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Goretti Pazos Gonzalez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complexo Hospitalario Universitario A Coruna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Han Yong Choi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raúl Sala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Oncologia de Rosario</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Cúndom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion Favaloro Para La Docencia e Investigacion Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Medgyasszay Balazs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veszprém Megyei Tüdőgyógyintézet Farkasgyepű</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tamás Pintér, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Petz Aladár Country Teaching Hospital Gyor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Cuvier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departmental Hosptital of Vendee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynn Maeda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nishinomiya Municipal Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Ballarat Health Services</name>
      <address>
        <city>Ballarat</city>
        <state>Victoria</state>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>East Bentleigh</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Klagenfurt am Worthersee</name>
      <address>
        <city>Klagenfurt am Worthersee</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Landesklinikum Krems</name>
      <address>
        <city>Krems</city>
        <zip>3500</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik fuer Anaesthesiologie, perioperative Medizin und allgemeine Intensivmedizin</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nuhr Medical Center</name>
      <address>
        <city>Senftenberg</city>
        <zip>3541</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital der Stadt Wien</name>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Oncologico del Sur (ICOS)</name>
      <address>
        <city>Temuco</city>
        <state>Region de La Araucania</state>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Rudolfa a Stefanie Benesov, a.s., Nemocnicni lekarna</name>
      <address>
        <city>Benesov</city>
        <zip>256 30</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Rudolfa a Stefanie Benesov, a.s., Onkologie</name>
      <address>
        <city>Benesov</city>
        <zip>256 30</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Rudolfa a Stefanie Benesov, a.s., Radiodiagnosticke oddeleni</name>
      <address>
        <city>Benesov</city>
        <zip>256 30</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radiologicke oddeleni, Nemocnice Horovice, NH Hospital, a.s.</name>
      <address>
        <city>Horovice</city>
        <zip>268 31</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Senimed s.r.o., Lekarna Nemocnice Horovice</name>
      <address>
        <city>Horovice</city>
        <zip>268 31</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologicka ambulance, Nemocnice Horovice, NH Hospital, a.s.</name>
      <address>
        <city>Horovice</city>
        <zip>26831</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Plzen</name>
      <address>
        <city>Plzen - Bory</city>
        <zip>305 99</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lekarna na Slovanske</name>
      <address>
        <city>Plzen</city>
        <zip>301 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urocentrum Plzen Research Site s.r.o.</name>
      <address>
        <city>Plzen</city>
        <zip>30100</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mestska nemocnice Plzen, Privamed a.s.</name>
      <address>
        <city>Plzen</city>
        <zip>323 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze, Fakultni poliklinika, Centrum pro lecbu bolesti</name>
      <address>
        <city>Praha 2</city>
        <zip>128 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze, Nemocnicni lekarna</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze, Radiodiagnosticka Klinika</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oblastni nemocnice Pribram, a.s., Nuklearni Medicina</name>
      <address>
        <city>Pribram V - Zdabor</city>
        <zip>261 95</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie- Pharmacie des essais cliniques</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHD Vendee</name>
      <address>
        <city>La Roche-Sur-Yon Cedex 9</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diagnoscan Magyarorszag Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinszky Korhaz es Rendelointezet / Onkologiai osztaly</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uzsoki Utcai Korhaz, Onkoradiologia</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uzsoki Utcai Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Systhemas Medicina Bt.</name>
      <address>
        <city>Cegled</city>
        <zip>2700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Veszprem Megyei Tudogyogyintezet Farkasgyepu</name>
      <address>
        <city>Farkasgyepu</city>
        <zip>8582</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Ltd., MISEK Hematology Department-CRU Co.</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Ltd., MISEK-CRU</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Josa Andras Hospital, Clinical Research Department</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Help-MR Diagnosztika Kft.</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet,</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Beer Yaacov</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Aichi Hospital</name>
      <address>
        <city>Okazaki</city>
        <state>Aichi</state>
        <zip>444-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Toyohashi Medical Center</name>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <zip>440-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gunma Prefectural Cancer Center</name>
      <address>
        <city>Ota</city>
        <state>Gunma</state>
        <zip>373-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KKR Sapporo Medical Center</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>062-0931</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nishinomiya Municipal Central Hospital</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8014</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Hospital of Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Takarazuka Municipal Hospital</name>
      <address>
        <city>Takarazuka</city>
        <state>Hyogo</state>
        <zip>665-0827</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Kumamoto Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Pharmacy, National Cancer Center (Drug Shipment only)</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local imaging facilities, Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <state>Jung-gu</state>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Pharmacy, Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Clinical Trial Pharmacy, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imaging facilities, Seoul National University Hospital (Imaging Only)</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Pharmacy, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imaging Facilities, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Pharmacy, Hallym University Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>05355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>05355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local imaging facilities, Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>05355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Pharmacy, Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local imaging facilities, Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Powiatowy Zespol Zakladow Opieki Zdrowotnej w Bedzinie,Oddzial Opieki Paliatywnej Szpital w Czeladzi</name>
      <address>
        <city>Czeladz</city>
        <state>Silesia</state>
        <zip>40-250</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pallmed Sp. z o.o. NZOZ Dom Sue Ryder</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej, Zespol Medyczno-Opiekunczy Alicja Kluczna</name>
      <address>
        <city>Dabrowa Gornicza</city>
        <zip>41-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospicjum im. Ks. Eugeniusza Dutkiewicza SAC w Gdansku</name>
      <address>
        <city>Gdansk</city>
        <zip>80-208</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stowarzyszenie Przyjaciol Chorych Hospicjum w Gliwicach NZOZ Hospicjum Milosierdzia Bozego</name>
      <address>
        <city>Gliwice</city>
        <zip>44-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stowarzyszenie Przyjaciol Chorych Hospicjum w Gliwicach, NZOZ Hospicjum Milosierdzia Bozego</name>
      <address>
        <city>Gliwice</city>
        <zip>44-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SCANiX Sp.z o.o</name>
      <address>
        <city>Katowice</city>
        <zip>40-057</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helimed Diagnostic Imaging Sp. z o.o., Sp. komandytowa</name>
      <address>
        <city>Katowice</city>
        <zip>40-760</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helimed Diagnostic Imaging Sp. z.o.o., Sp. komandytowa</name>
      <address>
        <city>Katowice</city>
        <zip>40-760</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SK Przemienienia Panskiego UM im. Karola Marcinkowskiego w Poznaniu,</name>
      <address>
        <city>Poznan</city>
        <zip>61-245</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wielkopolskie Centrum Onkologii w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>61-866</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinika Nowotworow Piersi i Chirurgii Rekonstrukcyjnej w Centrum Onkologii -Instytucie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrul De Oncologie, SF. Nectarie SRL</name>
      <address>
        <city>Craiova</city>
        <state>Dolj</state>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SC Oncolab SRL</name>
      <address>
        <city>Craiova</city>
        <state>Dolj</state>
        <zip>200385</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SC ONCOCENTER Oncologie Clinica SRL</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300210</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic C.F. 2 Bucuresti. Departament Oncologie, Sectia Medicala 2</name>
      <address>
        <city>Bucuresti</city>
        <zip>011464</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologický ústav sv. Alžbety s.r.o</name>
      <address>
        <city>Bratislava</city>
        <zip>812 50</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. MAGNET s.r.o</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Národný onkologický ústav</name>
      <address>
        <city>Bratislava</city>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>BIONT, a.s</name>
      <address>
        <city>Bratislava</city>
        <zip>842 29</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>DEMOMED s.r.o.</name>
      <address>
        <city>Nove Zamky</city>
        <zip>94001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica poliklinikou Nove Zamky (FNsP)-Nemocnicna lekaren</name>
      <address>
        <city>Nove Zamky</city>
        <zip>94034</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfamedis s.r.o, CT pracovisko</name>
      <address>
        <city>Presov</city>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivamed, s.r.o, Oddelenie nuklearnej mediciny</name>
      <address>
        <city>Presov</city>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wesper, A.S.</name>
      <address>
        <city>Presov</city>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SANERA, s.r.o.</name>
      <address>
        <city>Prešov</city>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MUDr. Viliam Cíbik,, PhD., s.r.o as a member of Slovak research center s.ro.</name>
      <address>
        <city>Pruské</city>
        <zip>018 52</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou Zilina, Urologicke oddelenie</name>
      <address>
        <city>Žilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Alcorcon. Servicio de Farmacia</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Alcorcon</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante. Servicio de Farmacia</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital La Moraleja</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NHS Lothian, Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NHS Lothian, Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velindre NHS Trust, Velindre Cancer Centre</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091061&amp;StudyName=A%20Phase%203%20Randomized%2C%20Double-blind%2C%20Placebo-controlled%2C%20Multicenter%20Study%20Of%20The%20Analgesic%20Efficacy%20And%20Safety%20Of%20The%20Subcutaneous%20Administration%20Of%20Tanezumab%20%28pf-04383119%29%20In%20Subjects%20With%20Cancer%20Pain%20Predominantly%20Due%20To%20Bone%20Metastasis%20Receiving%20Background%20Opioid%20Therapy</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>October 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic cancer bone pain</keyword>
  <keyword>Multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Musculoskeletal Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
